The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1461
February 2, 2015
View Complete Issue         Table of Contents 2019 
Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
February 2, 2015 (Issue: 1461)
The FDA has approved peramivir (Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had symptoms for no more than 2 days....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
Article code: 1461b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.